TASE takes AIM at Israeli high-tech

Reversing the trend of recent years, the TASE is gaining ground on the London Stock Exchange's Alternative Investment Market as more Israeli companies are choosing their home ground to raise capital.

By RYAN NADEL
September 19, 2006 08:56
1 minute read.

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Reversing the trend of recent years, the Tel Aviv Stock Exchange is gaining ground on the London Stock Exchange's Alternative Investment Market (AIM) as more Israeli high-tech companies are choosing their home ground to raise capital. "While in 2005 the majority of Israeli IPO's were on the AIM, this year most have been on the TASE," said Oren Bar-On, a partner at Ernst & Young Israel, during a workshop on listing strategies at the 10th annual Journey conference in Tel Aviv Monday. The session followed discussions outlining trends in the global wireless, semiconductor, Internet and nanotechnology markets and how they relate to Israel. Keynote speaker Nicholas Negroponte, founder and chairman of the MIT Media Lab, cited the Israeli appetite for risk as key to the country's success in these markets, as evidenced by the high number of Israeli tech companies on foreign exchanges. Members of the IPO panel said, however, that the recent performance of Israeli companies on international markets, in particular on the AIM, has been poor, leading to a natural movement back to the home exchange. The AIM has been seen as first stop for Israeli companies that do not yet meet the requirements set by the Nasdaq for listing. "The TASE has become part of the pre-Nasdaq process," said SVP Ronit Harel Ben-Ze'ev, manager of the economic department at the TASE. "It is often advantageous for Israeli companies to first go public in their home country," she said, stressing the "home court advantage" to a company's growth strategy. Deutsche Bank Israel's Zack Keinan said raising capital in foreign markets where the company does not conduct business might be ill-advised, as was selling shares to an investor base that didn't understand your growth story. Keinan also warned against moving to quickly to the initial public offering stage. Israeli companies turn to the public markets too soon and should consider other avenues before going public, he said. "Israeli companies go public long before their contemporaries in the US or Europe," Keinan said. "Good quality companies, where management has good control, should consider staying private." Meanwhile, London-based analysts gave their own explanations for the slowdown in Israeli activity there. "There is a much more cautious appetite from institutions for IPO's," said Adam Hart, director of communications at investment house KBC Peel Hunt. "I expect the number of IPO's to fall slightly as the [AIM] market demands higher quality offerings than in the past."

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS